-94 ins/del ATTG NFKB1 gene variant is associated with lower susceptibility to myocardial infarction

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 9, 2011, Pages 679-684

  Boccardi, V ^a   Rizzo, M R ^a   Marfella, R ^a   Papa, M ^a   Esposito, A ^a   Portoghese, M ^b   Paolisso, G ^a   Barbieri, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Sassari Hospital   (Italy)

Author keywords

Atherosclerosis; Inflammation; NFKB1 gene variant

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NFKB1 PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HEART INFARCTION; HUMAN; MALE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; I-KAPPA B PROTEINS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC;

EID: 80052727186     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.12.012     Document Type: Article

References (26)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
2. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108:1664-1672.
3. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481-2485.
4. Barnes P.J., Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1993, 36:1066-1071. (7).
5. Collins T., Cybulsky M.I. NF-kappa B: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001, 107:255-264.
6. Valen G., Yan Z.Q., Hansson G.K. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001, 38:307-314.
7. Karin Michael, Delhase Mareille The IKB kinase (IKK) and NFk{cyrillic}B: key elements of proinflammatory signalling. Immunology 2000, 12:85-98.
8. Sun X.-F., Zhang H. NFk{cyrillic}B and NFk{cyrillic}BI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007, 22:1387-1398.
9. Brand K., Page S., Walli A.K., Neumeier D., Baeuerle P.A. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997, 82:297-304.
10. Bourcier T., Sukhova G., Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997, 272:15817-15824.
11. Ritchie M.E. Nuclear factor-kappa B is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998, 98:1707-1713.
12. Karban A.S., Okazaki T., Panhuysen C.I., Gallegos T., Potter J.J., Bailey-Wilson, et al. Functional annotation of a novel NFk{cyrillic}B1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004, 13(1):35-45.
13. Park J.Y., Farrance I.K., Fenty N.M., Hagberg J.M., Roth S.M., Mosser, et al. NFk{cyrillic}B1 promoter variation implicates shear-induced NOS3 gene expression and endothelial function in prehypertensives and stage I hypertensives. Am J Physiol Heart Circ Physiol 2007, 293:H2320-H2327.
14. Borm M.E.A., von Bodegraven A., Mulder C.J.J. NFk{cyrillic}B1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005, 32:401-405.
15. Fontaine-Bisson Benedicte, Wolever Thomas M.S., Connelly Philip W., Corey Paul N., El-Sohemy Ahmed NFk{cyrillic}B -94 ins/del ATTG polymorphism modifies the association between dietary polyunsaturated fatty acids and HDL-cholesterol in two distinct populations. Atherosclerosis 2008.
16. Romzova M., Hohenadel D., Kolostova K., Pinterova D., Fojtikova M., Ruzickova S., et al. NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. Hum Immunol 2006, 67(9):706-713.
17. Aberti K.G.M.M., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of WHO consultation. Diab Med 1998, 15:539-553. for the WHO Consultation.
18. Ohlsson B.G., Englund M.C., Karlsson A.L., Knutsen E., Erixon C., Skribeck H., et al. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappa B to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. J Clin Invest 1996, 98(1):78-89.
19. Heron E., Deloukas P., van Loon A.P. The complete exon-intron structure of the 156-kb human gene NFk{cyrillic}B1, which encodes the p105 and p50 proteins of transcription factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal transduction. Genomics 1995, 30(3):493-505.
20. Wilson S.H., Best P.J., Edwards W.D., Holmes D.R., Carlson P.J., Celermajer D.S., et al. Nuclear factor-kappa B immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis 2002, 160:147-153.
21. Ito C.Y., Kazantsev A.G., Baldwin A.S. Three NF-Kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res 1994, 22:3787-3792.
22. Verma S., Badiwala M.V., Weisel R.D., et al. C-reactive protein activates the nuclear factor-kappa B signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003, 126:1886-1891.
23. Calabró P., Willerson J.T., Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108:1930-1932.
24. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
25. Liuzzo G., Santamaria M., Biasucci L.M., Narducci M., Colafrancesco V., Porto A., et al. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol 2007, 49(2):195-197.
26. Heinrich J., Balleisen L., Schulte H., Assmann G., van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994, 14:54-59.